We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sulfenic Acid Test May Enhance Early Detection of Breast Cancer

By LabMedica International staff writers
Posted on 22 Sep 2009
A recent report described the development of an immunochemical test for sulfenic acid, an early indicator of oxidative stress, and a possible marker for the first stages of breast cancer.

Sulfenic acid is produced when hydrogen peroxide reacts with the amino acid cysteine. More...
Proteins that have been modified by the addition of sulfenic acid are immunochemically distinct from the original. Applying this knowledge, investigators at the University of Michigan (Ann Arbor, USA) raised specific antibodies against sulfenic acid-modified proteins. The level of such proteins is an indicator of oxidative stress, a component of the "redox profile" that metabolically distinguishes normal and cancer cells.

The antibodies were labeled with a fluorescent tag that permitted detection of antibody binding by observation under a fluorescence microscope. Results obtained by using this system to determine the level of sulfenic acid modification of proteins in breast cancer cell lines were published in the September 10, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS). The results showed that the technique could be used to monitor differences in thiol redox status and revealed a diverse pattern of sulfenic acid modifications across different subtypes of breast tumors.

"For each line, we saw a very distinct pattern of sulfenic acid modifications," said senior author Dr. Kate S. Carroll, assistant professor of chemistry at the University of Michigan. "Whether the patterns we see will correlate with response to antioxidant treatment or other therapies that modulate oxidative stress level remains to be seen, but now we at least have a way to investigate that question.
Some of the modified proteins may not play any role, but I am sure it will turn out that many of them do. Once we find out which proteins are involved, we can target them directly rather than using global treatments like antioxidants. Being able to monitor a marker of oxidative stress that is associated with the activation of tumor cell growth pathways, particularly at an early stage, and then tailor treatments accordingly would allow for more targeted studies and might improve the odds of success with antioxidants and prooxidants," said Dr. Carroll.

Related Links:

University of Michigan



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.